Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F de Groot

Showing results (11-20 of 121) with videos related to

Pageof 13
Sort By:
Oncology (Williston Park, N.Y.)|January 22, 2013
Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a review of treatment and the integration of molecular markersNicole Shonka, Alba Brandes, John F De Groot
Cancer Journal (Sudbury, Mass.)|October 7, 2008
Bevacizumab and irinotecan in the treatment of recurrent malignant gliomasJohn F de Groot, Wai Kwan Alfred Yung
Neuro-Oncology|June 27, 2024
Proteasome inhibition for glioblastoma: Lessons learned and new opportunitiesS John Liu, David R Raleigh, John F de Groot
Advances in Experimental Medicine and Biology|January 1, 2022
Immunotherapy for Neuro-oncologyNazanin K Majd, Pushan R Dasgupta, John F de Groot
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2011
Multigene sets for clinical application in gliomaJohn F de Groot, Erik P Sulman, Kenneth D Aldape
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2009
Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapyAgda K Lucio-Eterovic, Yuji Piao, John F de Groot
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|January 27, 2020
Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastomaCarlos Kamiya-Matsuoka, Mohamed A Hamza, John F de Groot
Hematology/Oncology Clinics of North America|November 10, 2021
Isocitrate Dehydrogenase Wild-type Glial Tumors, Including GlioblastomaEvanthia Galanis, Patrick Y Wen, John F de Groot, et al.
Cancers|February 11, 2023
Preclinical Models of Low-Grade GliomasPushan Dasgupta, Veerakumar Balasubramanyian, John F de Groot, et al.
Cancer Cell|March 12, 2015
Seek and destroy: relating cancer drivers to therapiesEmmanuel Martinez-Ledesma, John F de Groot, Roel G W Verhaak
Pageof 13

Showing results (11-20 of 121) with videos related to

Sort By:
Pageof 13
Oncology (Williston Park, N.Y.)|January 22, 2013
Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a review of treatment and the integration of molecular markersNicole Shonka, Alba Brandes, John F De Groot
Cancer Journal (Sudbury, Mass.)|October 7, 2008
Bevacizumab and irinotecan in the treatment of recurrent malignant gliomasJohn F de Groot, Wai Kwan Alfred Yung
Neuro-Oncology|June 27, 2024
Proteasome inhibition for glioblastoma: Lessons learned and new opportunitiesS John Liu, David R Raleigh, John F de Groot
Advances in Experimental Medicine and Biology|January 1, 2022
Immunotherapy for Neuro-oncologyNazanin K Majd, Pushan R Dasgupta, John F de Groot
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2011
Multigene sets for clinical application in gliomaJohn F de Groot, Erik P Sulman, Kenneth D Aldape
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2009
Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapyAgda K Lucio-Eterovic, Yuji Piao, John F de Groot
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|January 27, 2020
Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastomaCarlos Kamiya-Matsuoka, Mohamed A Hamza, John F de Groot
Hematology/Oncology Clinics of North America|November 10, 2021
Isocitrate Dehydrogenase Wild-type Glial Tumors, Including GlioblastomaEvanthia Galanis, Patrick Y Wen, John F de Groot, et al.
Cancers|February 11, 2023
Preclinical Models of Low-Grade GliomasPushan Dasgupta, Veerakumar Balasubramanyian, John F de Groot, et al.
Cancer Cell|March 12, 2015
Seek and destroy: relating cancer drivers to therapiesEmmanuel Martinez-Ledesma, John F de Groot, Roel G W Verhaak
Pageof 13